M. Cazzola (Roma (RM), Italy), H. Kerstjens (Groningen, Netherlands)
Late Breaking Abstract - Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids.
A. Mathioudakis (Manchester, United Kingdom), P. Foden (Manchester, United Kingdom), J. Vestbo (Manchester, United Kingdom)
|     |
Late Breaking Abstract - Holter ECG-based arrhythmia and heart rate analysis in patients with COPD receiving a fixed-dose combination of tiotropium/olodaterol versus its monocomponents
S. Andreas (Göttingen, Germany), U. Bothner (Ingelheim am Rhein, Germany), A. De La Hoz (Ingelheim am Rhein, Germany), I. Kloer (Ingelheim am Rhein, Germany), M. Trampisch (Ingelheim am Rhein, Germany), P. Alter (Marburg, Germany)
| |
Late Breaking Abstract - Blood eosinophil counts and treatment response in COPD: analyses of IMPACT
S. Pascoe (Collegeville, PA, United States of America), N. Barnes (Brentford, United Kingdom), G. Brusselle (Ghent, Belgium), C. Compton (Brentford, United Kingdom), G. Criner (Philadelphia, PA, United States of America), M. Dransfield (Birmingham, AL, United States of America), D. Halpin (Exeter, United Kingdom), M. Han (Ann Arbor, Michigan, United States of America), B. Hartley (Twickenham, United Kingdom), E. Hilton (Brentford, United Kingdom), P. Lange (Copenhagen, Denmark), S. Lettis (Uxbridge, United Kingdom), D. Lipson (Collegeville; Philadeliphia, PA, United States of America), D. Lomas (London, United Kingdom), F. Martinez (New York, United States of America), A. Papi (Ferrara, Italy), N. Roche (Paris, France), R. Van Der Valk (Brentford, United Kingdom), R. Wise (Baltimore, Maryland, United States of America), D. Singh (Manchester, United Kingdom)
| |
Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK
A. Ismaila (Hamilton, ON, Canada), V. Paly (Philadelphia, PA, United States of America), M. Schroeder (Brentford, United Kingdom), A. Martin (Uxbridge, United Kingdom), J. Li (Boston, MA, United States of America), S. Lettis (Uxbridge, United Kingdom), N. Risebrough (Toronto, ON, Canada)
| |
Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening
D. Singh (Manchester, United Kingdom), G. Criner (Philadelphia, PA, United States of America), N. Day (Stockley Park West, Uxbridge, Middlesex, United Kingdom), M. Dransfield (Birmingham, AL, United States of America), D. Halpin (Exeter, United Kingdom), M. Han (Ann Arbor, Michigan, United States of America), C. Jones (Research Triangle Park, NC, United States of America), S. Kilbride (Stockley Park West, Uxbridge, Middlesex, United Kingdom), P. Lange (Copenhagen, Denmark), D. Lipson (Collegeville/Philadelphia, PA, United States of America), D. Lomas (London, United Kingdom), S. Pascoe (Collegeville, PA, United States of America), M. Tabberer (Stockley Park West, Uxbridge, Middlesex, United Kingdom), R. Wise (Baltimore, MD, United States of America), F. Martinez (New York, NY, United States of America)
| |
Late Breaking Abstract - Reduction of COPD exacerbations with extrafine single inhaler triple therapy: post-hoc analysis by exacerbation treatment of the TRIBUTE study
L. Fabbri (Ferrara, Italy), D. Singh (Manchester, United Kingdom), I. Valente (Parma, Italy), A. Guasconi (Parma, Italy), H. Prunier (Parma, Italy), G. Georges (Cary, United States of America), A. Papi (Ferrara, Italy)
| |
Late Breaking Abstract - Extrafine single inhaler triple therapy improves quality of life in COPD. Analysis of SGRQ subdomains of the TRIBUTE Study
L. Fabbri (Ferrara, Italy), D. Singh (Manchester, United Kingdom), I. Valente (Parma, Italy), A. Guasconi (Parma, Italy), H. Prunier (Parma, Italy), G. Georges (Cary, United States of America), A. Papi (Ferrara, Italy)
| |
Late Breaking Abstract - Pharmacokinetic and pharmacodynamic interactions between components of extrafine formulation of BDP/FF/GB, a novel fixed-dose triple combination for asthma and COPD
M. Cella (Parma, Italy), L. Gheyle (Antwerp, Belgium), C. Garofalo (Parma, Italy), C. Beaudot (Cary, United States of America), G. Georges (Cary, United States of America)
| |